Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.
The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.
The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...
Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 ...
The most recent version of NG28, the National Institute for Health and Care Excellence's (NICE) guidelines for managing type 2 diabetes in adults, has been released on February 18, 2026.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results